Back to search

Article

Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer

2025-08-30

Abstract excerpt

<h4>ABSTRACT</h4> The addition of CDK4/6 inhibitors to endocrine therapy has significantly improved outcomes in HR+/HER2-breast cancer. However, variable patient responses and acquired resistance remain a clinical challenge. We therefore defined the comprehensive molecular response to palbociclib, the most clinically used CDK4/6 inhibitor. Global analyses of gene expression, protein abundance, splicing, and chrom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
67775318-d2e0-56d4-9010-117326641fe5
DOI
10.1101/2025.08.27.672587
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast CancerDOI 10.1101/2025.08.27.672587
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibSemantic proximity
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast CancersSemantic proximity
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer CellsSemantic proximity
Differential Expression and Prognostic Significance of CDK1 and CDK6 in Breast Cancer: A Multi-Omics ApproachSemantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and TranscriptomicsSemantic proximity
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclibSemantic proximity
Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer TherapySemantic proximity
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapySemantic proximity
Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity
Select a neighboring publication to make it the new centre.